Prof. Wasim Hanif

Discontinuation of GLP-1 when Hba1c normalises neutralises CV benefits. Important message to ICBs who are implementing this policy GLP-1 receptor agonist discontinuation and risks of major adverse cardiovascular events in adults with type 2 diabetes: bmjmedicine.bmj.com/content/5/1/e0…

@dromarwahab @parthaskar @kamleshkhunti @DrSdeG @drmohanv @DrSelvarajah @ChitraEndocrine @DrAmbrishMithal @idrlakshmi @FionaQuigs @ObesitySociety @GoggleDocs @AbbieSBrooks These are Biosimilars hence only require pharmacokinetic validation studies rather than RCT.

Sir, you are absolutely right but there is another twist in that story…. Most of these products originate from China and LACK robust, well-documented safety studies. In fact, there is limited clarity regarding their source and whether they are approved or even in use in their country of origin. Therefore, I have significant concerns about their safety profile. While their efficacy in terms of weight reduction appears promising, in pharmacotherapy, safety must always remain the foremost priority, particularly with GLP-1–based agents, given their potential immunogenic nature. I am currently engaged in conducting studies on these agents and will be pleased to share my findings with you soon.

Bookmark this one The #NHS cannot afford present costs of #AntiObesity medications India will - likely- show the way & hold a clue For good or bad? The UK health system is heading towards a world of generics and unaffordabilty of most other things @kamleshkhunti @DrSdeG @ShivaniM_KC @NeilFlochMD bbc.co.uk/news/articles/…

The rising prevalence of Diabetes globally…will reach approximately 1 Billion by 2050. Time to act for socio-political policy makers @TheLancetEndo @DUK_research @WHO @EASDnews @IntDiabetesFed

MASALA Study Suggests Earlier Cardiovascular Vigilance Needed for People With South Asian Ancestry jamanetwork.com/journals/jama/…

Top company and drug sales for 2025. Obesity and Cancer drugs lead the way. Obesity is now recognised commercially as a disease with effective treatment options. Prevention, lifestyle choices have fallen by the wayside @kamleshkhunti @DrAmbrishMithal @docanoopmisra

Sleep your way to better metabolic health - thelancet.com/journals/landi…

GLP-1-based therapies for diabetes, obesity and beyond nature.com/articles/s4157…

Novel GLP-1-based Medications for Type 2 Diabetes and Obesity academic.oup.com/edrv/article-a…

The question patients ask about GLP-1 therapy for weight loss…is do we need to take it forever? The answer is more nuanced than a Yes. Key to long term success is in how we manage weight maintenance phase by increasing physical activity and behaviour change.

Explaining weight gain after stopping GLP1….Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation - pubmed.ncbi.nlm.nih.gov/39892489/

@ShivaniM_KC @DUK_research 😱😱😱 cannot believe @DUK_research the picture is of speaker of the session 😢

I’m in back to backs and my WhatsApp and emails are going nuts and why you might ask? This name switch humdinger from @DUK_research 😂😂😂 Should I change careers?? 🤣

Relevant paper for those currently fasting 🌙🕌 SGLT2 inhibitors during Ramadan? Meta-analysis (12 studies, n=3,625)- mainly observational studies ✔️ Lower risk of symptomatic hypoglycaemia (RR 0.53) ✔️ ↓ BP modestly ⚠️ Higher risk of postural dizziness (RR 6.39) & hypotension (RR 4.43) 📊 HbA1c, weight, renal function ≈ similar SGLT2i may be safe during fasting-but caution is warranted. Larger RCTs needed. pmc.ncbi.nlm.nih.gov/articles/PMC12…

@DrAmbrishMithal Ambrish the NICE @NICEComms TA1028 has approved the use of these in people above BMI >35 and one co morbidity based on clinical and cost effectiveness. ICB are dragging their feet and not implementing Around 2 million buying it privately. Perhaps only option “bribe to prescribe “

I don't understand how #NHS works But this certainly seems bizarre. Incentive to educate patients about obesity- laudable Incentive to diagnose and treat obesity - understandable. Bonus to prescribe drugs!! Unheard of. Drugs are supposed to be prescribed based on clinical situations and guidelines. Not based on bonuses! Almost seems like an industry-govt nexus at play! I hope I am wrong. What say @kamleshkhunti @parthaskar @docwas bbc.com/news/articles/…

Risk of all–cause death and pancreatic events following GLP-1 RA initiation in people…. GLP-1 RA use was associated with substantially reduced all-cause death but a small increased risk of acute pancreatitis, particularly during early treatment. link.springer.com/article/10.118…

Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits - thelancet.com/journals/lance…

@parthaskar @AMP86793444 @Rezaidi @SamaraAfzal @DrAmbrishMithal @AskDrShashank @SEN_Cricket @drpratikc @dramitaol @Dr__Sarmy This is Gambhirnomics making number 1 T20 team rankings struggling to get into semi finals in their home country @AskDrShashank

So..after all the chatter around #T20WorldCup Group 1: #India chances low (depends on what #WI does) Group 2: #NZ need to win 1 out of their 2- and then #Pak & #SL out So a semifinal line up with No Subcontinent team possible And no #Australia Who predicted that? 🙂

Out two Meta-analysis on using behavioural sleep intervention to improve metabolic parameters led by brilliant Dr Sam Mostafa @uhbtrust @UHBDiabetes @kamleshkhunti @unibirmingham

Preliminary evidence that using behavioural #sleep interventions in adults with poor sleep health can ⬇️ #bloodpressure & #HbA1c levels. Our 2 recent meta-analyses: ? A novel lifestyle target for CVD prevention @AbdTahrani @docwas @DiabetesUK @BloodPress_UK @ISHBP @sleepassoc

@dromarwahab @DrOsamaIshtiaq1 @m_alikaramat @parthaskar @SanjayKalraDr1 @DiabetesUK @AmDiabetesAssn @IntDiabetesFed @Kashifabbasiary @EHTASHAMAHMAD13 Congratulations @dromarwahab well done

@DrOsamaIshtiaq1 @m_alikaramat @parthaskar @SanjayKalraDr1 @docwas @DiabetesUK @AmDiabetesAssn @IntDiabetesFed @Kashifabbasiary @EHTASHAMAHMAD13 JazakAllah Khair

ALHUMDULILLAH another successful event by Umar Diabetes Foundation Driving Access in Diabetes & Obesity Care – Promoting Healthier Communities 🇵🇰 Novo Nordisk officially handed over a Mobile Health Unit to Umar Diabetes Foundation (UDF) at Pakistan Institute for Parliamentary Services, marking a major step in tackling diabetes and obesity in Pakistan. Former Prime Minister Honorable Raja Pervez Ashraf called these “silent emergencies” and praised UDF’s practical, community-based model, urging nationwide scaling. He also praised the efforts of Dr Muhammad Umar Wahab for his honorary work and leadership qualities. Senior journalist Hamid Mir hailed the initiative as a humanitarian mission, calling it hope, dignity, and inclusion for underserved communities. He lauded Dr. Muhammad Umar Wahab for his visionary leadership and commitment to restoring hope and protecting families from the silent crisis of diabetes and obesity. Dr. Zafar Mirza highlighted prevention, policy reform, and strong public health systems, while Dr. Shahzad Alam Khan emphasized national coordination to fight non-communicable diseases. Danish Ambassador Embassy of Denmark in Pakistan Her Excellency Maja Mortensen reaffirmed Denmark’s support and appreciated Umar Diabetes Foundation - UDF for their work and dedication in serving humanity. A formal MoU was signed between the Danish Ambassador and UDF to strengthen mobile health outreach and preventive care. Novo Nordisk Pakistan, represented by Mr Rashed Butt reaffirmed its commitment to expanding access to quality diabetes care. Dr. Muhammad Umar Wahab outlined how climate change, urbanization, and lifestyle shifts accelerate non-communicable diseases and stressed preventive policies, community education, early detection, and mobile healthcare outreach. Justice (R) Mian Muhammad Ajmal, Chairman UDF, stated the Mobile Health Unit symbolizes justice in healthcare, ensuring no one is deprived of treatment due to poverty or distance. The Mobile Health Unit will provide free screening, diagnostics, consultations, insulin, education, and referrals, especially for rural and low-income communities. Together, this partnership represents hope, equity, and stronger healthcare access across Pakistan. @HamidMirPAK @AhmadJawadBTH @RPAPPP @DKinPK @zfrmrza @WHOPakistan @wasimakramlive @Samarjournalist @Kashifabbasiary